ArticleFrontiers in immunology2020
Potential CD8+ T Cell Cross-Reactivity Against SARS-CoV-2 Conferred by Other Coronavirus Strains.
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- The Association Between Previous Influenza Vaccination and COVID-19 Infection Risk and Severity: A Systematic Review and Meta-analysis.American journal of preventive medicine · 2022Pooled it
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19.The New England journal of medicine · 2021Trial
- SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses.Frontiers in immunology · 2021Trial
- A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Cell-free immuno-profiling on a genetically programmed biochip.Nature nanotechnology · 2026Article
- Outcomes of COVID-19 in the Omicron-predominant wave: large-scale real-world data analysis with a comparison to influenza.Pneumonia (Nathan Qld.) · 2025Article
- Pathogenesis of influenza and SARS-CoV-2 co-infection at the extremes of age: decipher the ominous tales of immune vulnerability.Advanced biotechnology · 2025Review
- Association between combination COVID-19-influenza vaccination and long COVID in middle-aged and older Europeans: A cross-sectional study.Human vaccines & immunotherapeutics · 2024Article
- Article
- Article
- Article
- Review
- Effectiveness of influenza vaccination against SARS-CoV-2 infection among healthcare workers in Qatar.Journal of infection and public health · 2023Article
- De novo design of anti-variant COVID-19 vaccine.Biology methods & protocols · 2023Article
- Exposed seronegative: Cellular immune responses to SARS-CoV-2 in the absence of seroconversion.Frontiers in immunology · 2023Review
- Performance and correlation of ten commercial immunoassays for the detection of SARS-CoV-2 antibodies.Heliyon · 2022Article
- Article
- A structural homology approach to identify potential cross-reactive antibody responses following SARS-CoV-2 infection.Scientific reports · 2022Article
- Influenza Vaccination and COVID-19 Outcomes in People Older than 50 Years: Data from the Observational Longitudinal SHARE Study.Vaccines · 2022Article
- One-Year Report of COVID-19 Impact on Geriatric Patients: a Bio-Psycho-Social Approach.Canadian geriatrics journal : CGJ · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
While individuals infected with coronavirus disease 2019 (COVID-19) manifested a broad range in susceptibility and severity to the disease, the pre-existing immune memory to related pathogens cross-reactive against SARS-CoV-2 can influence the disease outcome in COVID-19. Here, we investigated the potential extent of T cell cross-reactivity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that can be conferred by other coronaviruses and influenza virus, and generated an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.